Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of FITC-Adalimumab During Endomicroscopy in Crohn's Disease
NCT01275508Phase 2Completed
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Jan 2011
- Primary completion
- Apr 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of adalimumab in Crohn's disease, sponsored by FAU Erlangen-Nürnberg Medical Faculty. Started Jan 2011; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01275508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01275508.